DEF 14A: Bioventus Inc. Proposes Board Declassification and Director Elections at 2024 Annual Meeting

Bioventus Inc. is seeking stockholder approval for a charter amendment to declassify its Board of Directors and elect directors at the upcoming Annual Meeting on June 11, 2024.

Summary

• Bioventus Inc. is holding its Annual Meeting of Stockholders virtually on June 11, 2024, at 10:00 a.m. Eastern Time.
• The meeting will address three proposals: declassifying the Board of Directors, electing Class III directors, and ratifying the appointment of Grant Thornton as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The Board recommends voting FOR all proposals.
• If the Declassification Charter Amendment (Proposal 1) is approved, directors elected at the Annual Meeting will serve annual terms, phasing out the classified board by the 2026 Annual Meeting.
• If Proposal 1 is not approved, Class III directors will be elected to three-year terms expiring at the 2027 Annual Meeting.
• As of the Record Date, April 15, 2024, there were 63,827,617 shares of Class A common stock and 15,786,737 shares of Class B common stock outstanding, each entitled to one vote.
• The Board has nominated Robert E. Claypoole, Philip G. Cowdy, and Martin P. Sutter for election as Class III directors.
• The company's equity compensation plan includes 6,412,351 securities to be issued upon exercise of outstanding options and rights.
• The Board has adopted a Compensation Recovery Policy to comply with clawback rules under the Dodd-Frank Act.
• The company's non-employee director compensation policy provides an annual cash retainer of $55,000, with additional retainers for the Chairperson and committee members.
• The company has entered into a Tax Receivable Agreement (TRA) with the Continuing LLC Owner, which could result in significant payments.
• The company has a Related Party Transaction Policy for reviewing and approving transactions exceeding $120,000 with related persons.
• Stockholders may submit proposals for the 2025 Annual Meeting no later than December 27, 2024, for inclusion in the proxy materials, or between February 11, 2025 and March 13, 2025, for presentation at the meeting.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the company's strategic direction and governance practices. However, potential risks associated with the Tax Receivable Agreement and stockholder influence temper the overall sentiment.

Positives

• The proposed declassification of the Board of Directors aligns with corporate governance trends favoring annual director elections.
• The Board recommends voting FOR all proposals, indicating a unified front and clear direction for the company.
• The company has a Compensation Recovery Policy in place, demonstrating a commitment to accountability and ethical compensation practices.
• The company has a Related Party Transaction Policy in place, demonstrating a commitment to transparency and ethical business practices.

Negatives

• The Tax Receivable Agreement (TRA) could require significant payments to the Continuing LLC Owner, potentially impacting the company's cash flow.
• The Stockholders Agreement grants certain stockholders significant influence over board nominations and corporate governance decisions.
• The company's Related Party Transaction Policy requires review and approval of transactions exceeding $120,000 with related persons, which could indicate potential conflicts of interest.

Risks

• The Tax Receivable Agreement (TRA) could require significant payments to the Continuing LLC Owner, potentially impacting the company's cash flow and liquidity.
• The Stockholders Agreement grants certain stockholders significant influence over board nominations and corporate governance decisions, potentially limiting the influence of other stockholders.
• The company's Related Party Transaction Policy requires review and approval of transactions exceeding $120,000 with related persons, which could indicate potential conflicts of interest.
• The company is subject to securities class action litigation and may be subject to similar or other litigation in the future, which will require significant management time and attention, result in significant legal expenses and may result in unfavorable outcomes.

Future Outlook

The company plans to focus on steadily improving business fundamentals and execution to deliver profitable growth and create stakeholder value.

Management Comments

• Robert E. Claypoole, President and CEO, stated that Bioventus is well-positioned in large market segments with excellent technology and a talented team.
• Mr. Claypoole expressed excitement for the future and encouraged stockholders to vote in advance of the Annual Meeting.
• Mr. Claypoole is encouraged by the company's ability to address headwinds experienced in early 2023, deliver strong results, and improve liquidity.

Industry Context

The proposal to declassify the Board of Directors reflects a broader trend in corporate governance towards greater accountability and responsiveness to stockholder concerns, particularly within the institutional investor community.

Comparison to Industry Standards

• The move to declassify the board aligns with trends seen at companies like Medtronic (MDT) and Johnson & Johnson (J&J), which have adopted similar governance structures to enhance shareholder influence.
• The equity compensation plan is comparable to those offered by similar-sized medical device companies, such as ConMed Corporation (CNMD) and MiMedx Group, Inc. (MDXG), to attract and retain key personnel.
• The non-employee director compensation policy is in line with industry standards, providing a mix of cash retainers and equity awards to incentivize board members and align their interests with those of shareholders.

Management Changes

Corporate Governance

Related Party Transactions

• The company has entered into a Tax Receivable Agreement (TRA) with the Continuing LLC Owner, which could result in significant payments.
• The company has a Related Party Transaction Policy for reviewing and approving transactions exceeding $120,000 with related persons.
• The company has engaged in certain transactions with directors, executive officers, and beneficial holders of more than 5% of its Common Stock, including the IPO Merger and the Bioventus LLC Agreement.

Stakeholder Impact

• Approval of the Declassification Charter Amendment would give stockholders greater control over the composition of the Board of Directors.
• The election of directors will determine the leadership and strategic direction of the company.
• The ratification of Grant Thornton as the independent registered public accounting firm ensures the integrity of the company's financial reporting.
• The Compensation Recovery Policy promotes accountability and ethical compensation practices for executive officers.
• The Tax Receivable Agreement (TRA) could impact the company's cash flow and financial performance, potentially affecting shareholder value.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will file the Declassification Charter Amendment with the Secretary of State of Delaware promptly after stockholder approval is obtained.
• The Board will take prompt action to approve an amendment to the Bylaws to conform to the Charter with respect to the structure of the Boards classes and terms of office and other related provisions.

Key Dates

Keywords

Board of Directors, Annual Meeting, Proxy Statement, Declassification, Director Election, Grant Thornton, Compensation, Corporate Governance, Stockholders, Bioventus